Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00446836 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of Xyotax to Treat Prostate Cancer
A Phase 2 study, sponsored by The Methodist Hospital Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT00446836 is a Phase 2 study that has completed, run by The Methodist Hospital Research Institute. The registered enrollment target is 29 participants.
The verdict
NCT00446836, a Phase 2 study, has completed, sponsored by The Methodist Hospital Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Xyotax, a conjugate of the taxane drug paclitaxel, is effective in the treatment of prostate cancer that is no longer responsive to hormone therapy.
Interventions
- DRUG Paclitaxel polyglumex (Xyotax)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2005-03 |
| Est. Completion | 2008-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00446836
The ClinicalTrials.gov registry entry for NCT00446836 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Methodist Hospital Research Institute, which has 126 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Paclitaxel polyglumex (Xyotax) is the first listed.
NCT00446836 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00446836 about?
NCT00446836 is a clinical study titled "Efficacy and Safety Study of Xyotax to Treat Prostate Cancer". The purpose of this study is to determine whether Xyotax, a conjugate of the taxane drug paclitaxel, is effective in the treatment of prostate cancer that is no longer responsive to hormone therapy.
What is the current status of trial NCT00446836?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2005-03. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00446836?
The interventions under investigation include: Paclitaxel polyglumex (Xyotax) (DRUG).
Who is sponsoring clinical trial NCT00446836?
This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.